DorothySipkinsMDPhD

Oncology • Durham, NC

Associate Professor of Medicine, Duke University

Join to view full profile

Dr. Sipkins is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sipkins' full profile

Already have an account?

Office
2400 Pratt St.
Duke University
Durham, NC 27705
Phone+1 919-668-1002

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2005
Massachusetts General HospitalResidency, Internal Medicine, 1999 - 2002
Stanford University School of MedicineClass of 1999

Certifications & Licensure

NC State Medical License 2014 - 2025
IL State Medical License 2005 - 2014
MA State Medical License 2002 - 2007

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Publications & Presentations

PubMed

4 citations
Breast cancer exploits neural signaling pathways for bone-to-meninges metastasis.
Andrew E Whiteley, Danhui Ma, Lihua Wang, Seok-Yeong Yu, Claire Yin
Science. 2024-06-21
1 citations
Pan-PI3Ki targets multiple B-ALL microenvironment interactions that fuel systemic and CNS relapse.
Sarah M. Ridge, Andrew E. Whiteley, Hisayuki Yao, Trevor T. Price, Maegan L. Brockman
Leukemia & Lymphoma. 2021-08-06
74 citations
Leukaemia: a model metastatic disease
Andrew E. Whiteley, Trevor T. Price, Gaia Cantelli, Dorothy A. Sipkins
Nature Reviews. Cancer. 2021-05-05

Abstracts/Posters

PI3K_/_ Inhibitor, Copanlisib, Inhibits Acute Lymphoblastic Leukemia Cell Growth, Increases Survival and Inhibits CNS Disease Progression in Leukemic Mice
Dorothy A. Sipkins, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

GlycoMimetics to Share GMI-1359 and Galectin-3 Antagonist Program Data at AACR 2021 MeetingMarch 10th, 2021
First Patient with Advanced Breast Cancer Receives First Dose in Clinical Trial of GlycoMimetics' GMI-1359January 30th, 2020
GlycoMimetics Announces Plans to Initiate Breast Cancer Trial to Evaluate GMI-1359November 13th, 2019
Join now to see all